Compare Moderna, Inc. (MRNA) vs Range Resources Corporation Common Stock (RRC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Range Resources Corporation Common Stock — how do they compare? Moderna, Inc. trades at $224.94 (market cap $86.33B), while Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B). The key difference: Moderna, Inc. is far larger — about 8.7× Range Resources Corporation Common Stock's market cap, and Range Resources Corporation Common Stock pays a 0.94% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Range Resources Corporation Common Stock for 0 Days on average.
| MRNA | RRC | |
|---|---|---|
Market Cap | $86.33B | $9.93B |
Volume | 13,361,426 | 2,413,752 |
Sector | Health | Energy |
52-Week High | $226.30 | $47.65 |
52-Week Low | $22.36 | $33.43 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $10.94B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.
Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Range Resources Corporation Common Stock
Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.
Read more on RRC →
